About

Benjamin Rich is founder and CEO of InnoMx, a consultancy specializing in pharmacometrics, quantitative clinical pharmacology, model-informed drug development and regulatory strategy.

He has over 15 years of experience as a consultant, developing and using mathematical and statistical models to inform drug development programs. Since 2005, he has contributed to over a dozen regulatory fillings and drug approvals. All the while, he has endeavored to evolve the whole practice of pharmacometrics, through better frameworks and tools and more efficient processes. Which is why he has partnered with Pumas-AI, makers of the most forward-looking and cutting-edge pharmacometrics platform on the planet.

Particular areas of expertise include exposure-response analysis of time-to-event endpoints with time-varying exposure, pharmacokinetics of monoclonal antibodies, clinical trial simulations and interactive data analysis and visualization apps using the R Shiny framework.

He holds a Bachelors degree in Join Honours Mathematics and Computer Science and Ph.D. in Biostatistics from McGill university, as well as an M.Sc. in Bioinformatics from the Freie Universität Berlin.